Investing.com -- Wellgistics Health Inc (NASDAQ:WGRX) stock surged 9.2% on Monday after the health information technology company announced the commercial launch of diabetes prescription drug ...

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...

Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

The negotiated prices are a result of a program passed by Congress in 2022 as part of the Inflation Reduction Act (IRA). The ...

Drugs used to treat depression, asthma and diabetes were also on a list that Medicare will pay less to cover, the Centers for Medicare and Medicaid Services said.

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash ...

President Joe Biden speaks about his administration's plans to protect Social Security and Medicare and lower health care costs, Feb. 9, 2023, at the University of Tampa in Tampa, Fla. (AP ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and ...